Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers
| Autor: | S Sjögren, Lars Holmberg, Jonas Bergh, Mats Inganäs, Anders Lindgren |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Oncology
Adult Cancer Research Pathology medicine.medical_specialty medicine.drug_class Receptor ErbB-2 medicine.medical_treatment Mammary gland Breast Neoplasms Monoclonal antibody Gene product Breast cancer Predictive Value of Tests Internal medicine medicine Biomarkers Tumor Humans Survival rate Aged Aged 80 and over business.industry Middle Aged medicine.disease Prognosis Immunohistochemistry Radiation therapy Survival Rate medicine.anatomical_structure Predictive value of tests Lymphatic Metastasis Multivariate Analysis Female business |
| Zdroj: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 16(2) |
| ISSN: | 0732-183X |
| Popis: | PURPOSE To investigate the prognostic and predictive value of c-erbB-2 overexpression in breast cancer in relation to other prognostic markers. PATIENTS AND METHODS Paraffin-embedded tumors from 315 consecutive primary breast cancer patients were screened for c-erbB-2 protein (p185) overexpression by immunohistochemistry using the monoclonal antibody CB11. RESULTS c-erbB-2 protein overexpression was detected in 19% of tumors and was associated with shorter 5-year overall survival (OAS) rate compared with c-erbB-2-negative cases in the total patient material (58% and 77%, respectively; P = .004) and in the 96 node-positive patients (31% and 61%, respectively; P = .02), but not in node-negative patients. For 47 node-positive patients treated with adjuvant tamoxifen and radiotherapy, the 5-year OAS was 13% for c-erbB-2 overexpression and 75% for c-erbB-2-negative patients (P = .00004). The frequency of c-erbB-2 overexpression decreased with age at diagnosis. The prognostic value of c-erbB-2 on OAS was independent of age, node status, tumor size, histopathologic grade, hormone receptor status, S phase, p53 status, and adjuvant treatment. c-erbB-2 status added prognostic information to p53-negative and low S-phase cases, but not to p53-positive and high S-phase cases. Correspondingly, these only added information to c-erbB-2-negative cases. CONCLUSION c-erbB-2 protein overexpression may have a predictive value with regard to adjuvant therapy in node-positive patients, for whom adjuvant tamoxifen with radiotherapy appears insufficient in the presence of c-erbB-2 overexpression. Combination of conventional and newer tumor markers may identify patients with a worse prognosis within groups with a generally favorable prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|